The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines Brigette B.Y. MaFion SungAnthony T.C. Chan PRECLINICAL STUDIES 27 January 2009 Pages: 107 - 114
A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis Rosanna CozzolinoGaetano CalìPaolo Laccetti PRECLINICAL STUDIES 03 February 2009 Pages: 115 - 123
N-4-iodophenyl-N′-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles Emmanuelle MounetouElisabeth Miot-NoiraultJ. Claude Madelmont PRECLINICAL STUDIES 10 February 2009 Pages: 124 - 131
F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies Jing LiYang MengXiao-Guang Chen PRECLINICAL STUDIES 12 February 2009 Pages: 132 - 138
Comparison of the cytotoxic effect of lapachol, α-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells Eduardo J. S. SalustianoChaquip D. NettoPaulo R. R. Costa PRECLINICAL STUDIES 04 March 2009 Pages: 139 - 144
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice J. H. BeumerN. E. FrankeO. van Tellingen PRECLINICAL STUDIES 24 February 2009 Pages: 145 - 155
Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors Teresa G. HayesGerald S. FalchookAtul Varadhachary PHASE I STUDIES 24 February 2009 Pages: 156 - 162
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors R. L. OostendorpP. O. WitteveenJ. H. M. Schellens PHASE I STUDIES 30 April 2009 Pages: 163 - 170
Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial Sung Yong OhWon Seog KimCheolwon Suh PHASE II STUDIES 07 May 2009 Pages: 171 - 177
Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis Antoine AdenisCharles FertéNicolas Penel PHASE II STUDIES 08 May 2009 Pages: 178 - 184
Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction Simona PotenzaGuglielmo NastiAnnalisa Capuano SHORT REPORT 08 April 2009 Pages: 185 - 186
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug Miguel MuñozMarisa Rosso Preclinical Studies 17 January 2009 Pages: 187 - 193
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics Matthew D. GalskyTal ZaksDaniel D. Von Hoff Clinical Trial Methodology 06 March 2009 Pages: 194 - 198
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour Julien DomontChristophe MassardJean-Charles Soria SHORT REPORT 08 April 2009 Pages: 199 - 202
Erratum to: Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction Simona PotenzaGuglielmo NastiAnnalisa Capuano Erratum 25 February 2010 Pages: 203 - 203